Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹1464 Cr.
Stock P/E
25.3
P/B
—
Current Price
₹506.4
Book Value
₹ 0
Face Value
1
52W High
₹759
52W Low
₹ 476.9
Dividend Yield
0.97%

Amrutanjan Health. Overview

Business

Amrutanjan Health Care Ltd. is an Indian consumer healthcare company primarily engaged in the manufacturing and marketing of Ayurvedic and Over-The-Counter (OTC) products. Established in 1893, it is one of India's oldest companies in its segment. Its core business revolves around providing relief-oriented products for common ailments like pain, cold, and cough, alongside a growing portfolio of health and wellness products. The company makes money by selling these products through an extensive distribution network across India, including pharmacies, general stores, and modern trade channels, leveraging its strong brand heritage.

Revenue Mix

Amrutanjan's business is broadly categorized into:

Pain Management: This is the flagship segment, dominated by products like Amrutanjan Pain Balm, Joint Muscle Spray, and creams for various types of pain. This segment typically contributes the largest share of revenue.

Cough & Cold: Includes products like Amrutanjan Cold Rub and roll-ons designed to alleviate cold and flu symptoms.

Health & Wellness: This growing segment encompasses products such as Fruitnik health drinks, hand sanitizers, and other personal care items, aiming to diversify beyond traditional relief products.

Exact percentage contributions vary year-on-year, but Pain Management historically remains the dominant revenue driver.

Industry

Amrutanjan operates within the highly competitive Indian consumer healthcare and OTC pharmaceuticals market. This industry is characterized by a mix of large multinational corporations, domestic FMCG giants, and specialized Ayurvedic players. Amrutanjan holds a strong legacy position, particularly in the pain relief balm category, where its brand is a household name. It competes with players like Emami (Zandu Balm), Reckitt Benckiser (Moov), P&G (Vicks), Dabur, and Himalaya. Its positioning is built on a century-old heritage, trust in Ayurvedic formulations, and extensive distribution reach, especially in semi-urban and rural areas.

MOAT

Amrutanjan possesses several durable competitive advantages:

Brand Recognition & Heritage: Over 125 years of existence has built immense brand recall and trust, particularly for its pain balms, making "Amrutanjan" almost synonymous with the product category for many consumers.

Extensive Distribution Network: A deep and wide distribution network across India ensures product availability even in remote locations, a significant barrier to entry for new players.

Consumer Loyalty: Generations of consumers have used and trusted Amrutanjan products, leading to strong brand loyalty, especially for its core offerings.

Formulation Expertise: A long history of developing and refining Ayurvedic formulations gives it credibility in traditional remedies.

Growth Drivers

Key factors that can drive Amrutanjan's growth include:

Increasing Health & Wellness Awareness: Growing consumer focus on preventive healthcare and natural remedies fuels demand for its Ayurvedic and wellness products.

Product Portfolio Expansion: Launching new products in existing categories (e.g., specialized pain relief) and expanding into adjacent health and hygiene segments.

Deepening Market Penetration: Further expanding its distribution reach into untapped rural markets and strengthening presence in modern retail and e-commerce channels.

Premiumization: Introducing higher-value or specialized products that command better margins.

Demographic Shifts: An aging population could increase demand for pain management solutions.

Risks

Intense Competition: Facing stiff competition from well-funded domestic and international FMCG and pharmaceutical companies that have vast marketing budgets and distribution capabilities.

Raw Material Price Volatility: Fluctuations in the prices of key Ayurvedic and natural ingredients can impact production costs and profitability.

Changing Consumer Preferences: A shift towards modern medicine, different forms of natural remedies, or alternative wellness trends could impact demand for traditional products.

Regulatory Changes: Any changes in regulations related to manufacturing, marketing, or labeling of Ayurvedic and OTC products in India.

Counterfeit Products: Risk of fake products eroding brand trust and market share.

Management & Ownership

Amrutanjan Health Care Ltd. is a promoter-driven company, with the Sambhu Prasad family holding a significant stake and actively involved in its management. Mr. S. Sambhu Prasad serves as the Chairman and Managing Director. The management is generally perceived as conservative, focused on sustainable growth, and maintaining the company's long-standing heritage. The promoter holding typically hovers around 50-60%, indicating strong family control and alignment with long-term vision.

Outlook

Amrutanjan Health Care has a resilient business built on a foundation of strong brand equity and an extensive distribution network, particularly for its heritage pain management products. The company is strategically diversifying its product portfolio into the growing health and wellness segment, which offers avenues for future growth beyond its traditional core. While it operates in a highly competitive market against larger players, its established brand trust and Ayurvedic legacy provide a distinct advantage. The outlook suggests steady, albeit potentially moderate, growth driven by an expanding product range and increasing consumer demand for accessible, trusted healthcare solutions, balanced by the need to innovate and compete effectively against agile rivals.

Amrutanjan Health. Share Price

Live · BSE / NSE · Inception: 1936
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Amrutanjan Health. Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Amrutanjan Health. Profit & Loss

#(Fig in Cr.) Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 TTM
Net Sales 105 143 138 142 167 187
Other Income 5 5 4 4 4 6
Total Income 110 148 142 146 171 192
Total Expenditure 92 125 120 121 143 156
Operating Profit 18 23 22 25 28 36
Interest 1 3 2 2 1 0
Depreciation 2 4 4 4 3 3
Exceptional Income / Expenses -0 -0 0 0 0 0
Profit Before Tax 15 16 15 19 24 33
Provision for Tax 5 6 5 7 9 12
Profit After Tax 10 10 10 12 15 21
Adjustments 0 0 0 0 0 0
Profit After Adjustments 10 10 10 12 15 21
Adjusted Earnings Per Share 3.4 3.3 3.5 4.3 5.1 7

Amrutanjan Health. Balance Sheet

#(Fig in Cr.) Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016
Shareholder's Funds 101 77 82 89 95 109
Minority's Interest 0 0 0 0 0 0
Borrowings 4 6 0 0 0 0
Other Non-Current Liabilities 4 4 4 4 3 4
Total Current Liabilities 47 37 38 27 26 28
Total Liabilities 157 124 124 120 124 140
Fixed Assets 52 33 30 27 24 29
Other Non-Current Assets 30 31 31 15 17 11
Total Current Assets 74 61 63 78 83 100
Total Assets 157 124 124 120 124 140

Amrutanjan Health. Cash Flow

#(Fig in Cr.) Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016
Opening Cash & Cash Equivalents 28 24 7 9 29 31
Cash Flow from Operating Activities 6 4 9 17 18 21
Cash Flow from Investing Activities -29 14 8 16 -5 4
Cash Flow from Financing Activities 20 -27 -14 -14 -12 -13
Net Cash Inflow / Outflow -4 -9 2 20 1 12
Closing Cash & Cash Equivalent 24 15 9 29 31 42

Amrutanjan Health. Ratios

# Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016
Earnings Per Share (Rs) 3.37 3.3 3.46 4.26 5.1 7.04
CEPS(Rs) 3.97 4.51 4.74 5.49 6.2 8.18
DPS(Rs) 1.5 1.5 1.5 1.6 1.75 1.93
Book NAV/Share(Rs) 33.46 26.43 28.14 30.53 32.48 37.2
Core EBITDA Margin(%) 12 12.21 12 14.05 13.48 15.72
EBIT Margin(%) 14.52 12.67 12.38 14.21 14.21 16.92
Pre Tax Margin(%) 14.01 10.58 10.67 13.03 13.81 16.69
PAT Margin (%) 9.3 6.46 6.97 8.36 8.52 10.51
Cash Profit Margin (%) 10.95 8.83 9.54 10.78 10.36 12.22
ROA(%) 7.43 6.86 8.15 10.18 12.21 15.57
ROE(%) 10.32 10.79 12.68 14.51 16.18 20.2
ROCE(%) 13.86 16.36 18.28 21.73 25.54 31.74
Receivable days 36.75 36.1 57.74 65.29 54.9 51.48
Inventory Days 29.31 28.71 29.44 23.26 18.09 16.39
Payable days 78.5 48.66 58.05 50.22 42.45 46.28
PER(x) 18.39 23.26 16.77 14.74 46.91 29.64
Price/Book(x) 1.85 2.9 2.06 2.06 7.36 5.61
Dividend Yield(%) 2.42 1.96 2.59 2.55 0.73 0.92
EV/Net Sales(x) 1.84 1.61 1.23 1.1 3.99 3.02
EV/Core EBITDA(x) 10.8 10.12 7.83 6.31 23.65 15.47
Net Sales Growth(%) 17.42 35.8 -3.84 2.97 17.53 12.11
EBIT Growth(%) -15.55 18.62 -5.09 17.79 17.56 33.23
PAT Growth(%) -10.98 -5.65 5 23 19.77 38.06
EPS Growth(%) -10.98 -2.2 5 23 19.77 38.06
Debt/Equity(x) 0.3 0.28 0.18 0.09 0.03 0.02
Current Ratio(x) 1.56 1.66 1.67 2.87 3.2 3.59
Quick Ratio(x) 1.35 1.3 1.4 2.55 2.87 3.27
Interest Cover(x) 28.26 6.05 7.24 11.97 34.96 75.81
Total Debt/Mcap(x) 0.16 0.1 0.09 0.04 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +12% +11% +12% —
Operating Profit CAGR +29% +18% +15% —
PAT CAGR +40% +28% +16% —
Share Price CAGR -31% -7% -10% +9%
ROE Average +20% +17% +15% +14%
ROCE Average +32% +26% +23% +21%

Amrutanjan Health. Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 46.52 %
FII 2.44 %
DII (MF + Insurance) 12.28 %
Public (retail) 38.76 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 50.5950.5946.5246.5246.5246.5246.5246.5246.5246.52
FII 1.381.552.342.32.32.412.382.272.172.44
DII 7.297.3210.611.1211.4112.712.91312.6612.28
Public 40.7440.5440.5440.0639.7838.3738.238.2138.6538.76
Others 0000000000
Total 100100100100100100100100100100

Amrutanjan Health. Peer Comparison

Pharmaceuticals & Drugs Edit Columns

Amrutanjan Health. Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Amrutanjan Health. Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 46.52%.
  • Debtor days have increased from 42.45 to 46.28days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp